Accuray Incorporated · NASDAQ:ARAY
Accuray — Q4 FY2024 Earnings Presentation
12 slides from Accuray's earnings presentation, Aug 14, 2024
Slide 1: Q4'FY24 Earnings Call Supplemental Presentation
Q4’FY24 Earnings Call Supplemental Presentation August 14, 2024 Exhibit 99.2
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are
Slide 3: Closing the Gaps to Cancer Care
Closing the Gaps to Cancer Care Advance Care by providing solutions that address the biggest pain points in RT Drive Patient Access to radiotherapy treatments in developed and high potential underserved markets Delight Customers by ensuring high operational performance so no patient is rescheduled H
Slide 4: Our Strategic Growth Plan: Key Pillars
Our Strategic Growth Plan: Key Pillars Guided by Our Vision: To expand the curative power of radiation therapy to improve as many lives as possible Outpace the Market and Grow Customer Base Improve Profitability and Operational Excellence Expand Service and Solutions Recurring Revenue Strengthen Bal
Slide 5: Q4'FY24 Highlights
Q4’FY24 Highlights Implemented first installations of the VitalHold™ surface-guided radiation therapy (SGRT) on the Radixact® System in Japan Gained CE Mark for the Accuray Helix™, a configuration of the Radixact® Treatment Delivery System, designed for India and other high potential markets where t
Slide 6: Expanding Access to Precision Cancer Care
Expanding Access to Precision Cancer Care Accuray Helix™ Tomo® C Locally Manufactured, China Solution Manufactured in Madison, Wisconsin Fueling Growth in China Type B Market Unique Features Designed for Workflow Efficiency NMPA Approval CE Mark
Slide 7: Q4'FY24 and FY24 Financials
Q4’FY24 and FY24 Financials Solid financial performance Highlights $M Q4 Y/Y FY’24 Y/Y Y/Y XFX2 Gross Orders $95.5M 8% 10% $342.1M 10% 11% Revenues $134.3M 14% 16% $446.6M (0%) 0% Product $79.7M 28% 29% $234.2M 0% 1% Service $54.6M (2%) 0% $212.4M (1%) (1%) Op. Expenses $31.6M (17%) $142.4M (6%) R&D
Slide 8: FY25 Guidance
FY25 Guidance Revenue Adjusted EBITDA1 FY25 Guidance Range $27.5M - $29.5M +40% - 50% 1 Adjusted EBITDA is a non-GAAP measure. Please see Slide 12 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure. $ in millions % = YoY Growth $460M - $470M +3% - 5%
Slide 9: Thank you
ACCURAY Thank you
Slide 10: GAAP to Adjusted EBITDA Q4 FY'24 and Q4 FY'23
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Three Months Ended June 30, Three Months Ended June 30, 2023 2024 $ $ $ $ 3,387 1,507 2,042 2,686 471 10,093 (2,556) 1,097 2,452 2,735 580 5,208 ERP and E
Slide 11: GAAP to Adjusted EBITDA FY2024 and FY2023
$K GAAP net income (loss) Stock-based compensation Interest expense, net Restructuring charges Depreciation and amortization Twelve Months Ended June 30, Twelve Months Ended June 30, 2023 2024 $ $ (15,545) 5,905 9,483 10,676 2,633 3,725 (9,280) 4,527 10,053 10,340 2,738 2,492 ERP and ERP related exp
Slide 12: GAAP to Adjusted EBITDA FY'25 Forward Looking Guidance
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization To From $ $ $ $ (5,000) 6,500 10,000 13,000 3,000 27,500 (3,000) 6,500 10,000 13,000 3,000 29,500 GAAP to Adjusted EBITDA FY’25 – Forward Looking Guidance